Benralizumab Exacerbation Study

• Research type

  Research Study

• Full title

  Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory cohort study

• IRAS ID

  256756

• Contact name

  Rekha Chaudhuri

• Contact email

  rekha.chaudhuri@ggc.scot.nhs.uk

• Sponsor organisation

  NHS Greater Glasgow and Clyde

• Eudract number

  2018-003699-11

• Duration of Study in the UK

  2 years, 10 months, 2 days

• Research summary

  Asthma, a common inflammatory condition, is usually well managed with inhaled corticosteroids that target eosinophilic inflammation. In severe asthma cases the management and prevention of exacerbations still presents a problem. This study aims to understand the nature of asthma exacerbations that occur despite benralizumab therapy to help improve severe asthma management.

  The study will involve 150 patients recruited from severe asthma clinics in NHS hospitals UK wide. Participants will receive benralizumab treatment for either 56 or 80 weeks.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  19/LO/0571

• Date of REC Opinion

  13 Jun 2019

• REC opinion

  Further Information Favourable Opinion